Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Enliven Therapeutics (Nasdaq: ELVN) said company management will present in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 10:30 a.m. ET. The event will be webcast live and archived for 90 days on the investor relations site.

News Market Reaction – ELVN

+1.16%

1 alert

+1.16% News Effect

+$19M Valuation Impact

$1.68B Market Cap

0.0x Rel. Volume

On the day this news was published, ELVN gained 1.16%, reflecting a mild positive market reaction. This price movement added approximately $19M to the company's valuation, bringing the market cap to $1.68B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ENABLE patients: 60 patients MMR rate: 69% MMR rate: 47% +5 more

8 metrics

ENABLE patients 60 patients Phase 1b ENABLE trial enrollment as of Dec 22, 2025

MMR rate 69% Cumulative MMR by 24 weeks, 60/120 mg cohorts in ENABLE Phase 1b

MMR rate 47% Cumulative MMR by 24 weeks, 80 mg cohort in ENABLE Phase 1b

Cash & securities $477.6M Cash, cash equivalents and marketable securities, Q3 2025

Net loss $20.1M Q3 2025 net loss

Inducement options 875,000 shares CEO inducement stock option grant at $18.77 exercise price

Conference time 10:30 a.m. ET Scheduled TD Cowen fireside chat on March 3, 2026

Webcast archive 90 days Duration webcast will remain available after the conference

Market Reality Check

Price: $29.44 Vol: Volume 787,529 is close t...

normal vol

$29.44 Last Close

Volume Volume 787,529 is close to the 20-day average of 771,939 (relative 1.02x), suggesting typical trading activity ahead of the event. normal

Technical Price at $28.32 is trading above the 200-day moving average of $20.92 and within 6% of the 52-week high of $30.22.

Peers on Argus

ELVN gained 3.17% while peers showed mixed but mostly positive moves: RCUS +5.76...

ELVN gained 3.17% while peers showed mixed but mostly positive moves: RCUS +5.76%, NUVB +2.36%, ZYME +1.94%, NTLA +0.89%, and DNTH roughly flat at -0.02%. The momentum scanner did not flag a coordinated sector move, indicating trading was more stock-specific.

Common Catalyst One peer, Arcus Biosciences (RCUS), reported earnings and a pipeline update, but there is no broad, shared catalyst across the group.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Clinical data update	Positive	+50.3%	Initial Phase 1b ENABLE data for ELVN-001 in CML with strong MMR rates.
Jan 07	Leadership/board changes	Positive	+2.2%	Board refresh to support advancement of ELVN-001 toward Phase 3 in 2026.
Dec 11	Equity inducement grant	Neutral	-6.9%	Large CEO inducement stock option grant under 2025 Inducement Equity Incentive Plan.
Dec 11	New CEO appointment	Positive	-6.9%	Appointment of Rick Fair as CEO to drive planned pivotal ELVN-001 trial.
Nov 12	Earnings and update	Positive	+3.4%	Q3 2025 results with strong cash position and plans for a 2026 Phase 3 trial.

Pattern Detected

ELVN has shown strong positive reactions to clinical updates, more moderate moves on routine corporate news, and occasional selloffs around leadership and equity compensation announcements.

Recent Company History

Over the last few months, ELVN highlighted advancing its CML program and strengthening leadership. On Nov 12, 2025, it reported Q3 2025 results with $477.6M in cash and runway into 2029. December brought a new CEO and related inducement grants. In early January, management changes and positive Phase 1b ENABLE data for ELVN-001 drove notable price reactions. Today’s conference participation fits into ongoing investor outreach following these clinical and strategic milestones.

Market Pulse Summary

This announcement highlights ELVN’s participation in a TD Cowen health care conference, extending it...

Analysis

This announcement highlights ELVN’s participation in a TD Cowen health care conference, extending its outreach following recent leadership changes, strong Phase 1b ENABLE data, and a solid cash position of $477.6M reported for Q3 2025 with runway into 2029. Investors may focus on how management frames the path to a planned Phase 3 trial for ELVN-001, capital allocation, and any incremental clinical or regulatory color provided during the fireside chat and webcast.

Key Terms

phase 1b, phase 3, mmr, deep molecular response, +4 more

8 terms

phase 1b medical

"reported initial Phase 1b ENABLE data for ELVN-001 in relapsed, refractory..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

phase 3 medical

"planned pivotal Phase 3 trial of ELVN-001 in chronic myeloid leukemia (CML)..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

mmr medical

"cumulative MMR reached 69% by 24 weeks in the randomized 60/120 mg cohorts..."

MMR is a combined vaccine that protects against measles, mumps and rubella, three contagious viral illnesses. For investors, MMR-related news matters because changes in approvals, manufacturing capacity, supply, or public vaccination programs can quickly affect revenues, costs and reputation for vaccine makers and healthcare providers—similar to how a disruption to a key product line can alter a company's sales and market value.

deep molecular response medical

"Deep molecular response was 35% in 60/120 mg versus 16% in 80 mg."

A deep molecular response is when a highly sensitive blood test can no longer detect or finds only trace amounts of disease-causing genetic material after treatment, indicating the illness has been driven down to very low levels. For investors, it signals a therapy’s strong effectiveness and durability, can support regulatory approvals or premium pricing, and may increase the likelihood of patients safely stopping treatment — similar to showing a factory has reduced its defect rate from common to nearly zero.

inducement stock option grant financial

"announced on December 11, 2025 an inducement stock option grant tied to..."

An inducement stock option grant is a package of stock options given to a new executive or employee as a hiring incentive, meant to reward them for joining and to align their interests with shareholders. For investors it matters because these grants can increase future share count if exercised, add to a company’s reported compensation costs, and signal management’s plan to retain or motivate key talent—think of it as a signing bonus paid in potential future ownership rather than cash.

rule 10b5-1 trading plan regulatory

"The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

form 4 regulatory

"[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

form 144 regulatory

"[144] Enliven Therapeutics, Inc. SEC Filing"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

AI-generated analysis. Not financial advice.

BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. ET.

The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference-302697474.html

SOURCE Enliven Therapeutics, Inc.

FAQ

When will Enliven Therapeutics (ELVN) present at the TD Cowen Health Care Conference?

Enliven will present on March 3, 2026 at 10:30 a.m. ET in a scheduled fireside chat. According to the company, management will discuss corporate updates and answer investor questions during the live session.

How can investors watch the ELVN fireside chat at TD Cowen on March 3, 2026?

Investors can watch via a live webcast on Enliven's investor relations website. According to the company, the webcast link will be available on the investor relations section and will stream the live presentation.

Will Enliven Therapeutics (ELVN) archive the TD Cowen webcast and for how long?

Yes, the webcast will be archived for 90 days after the live event on the company's investor site. According to the company, the archived recording will remain accessible for replay through that retention period.

What topics will Enliven (ELVN) management likely cover during the March 3, 2026 fireside chat?

The fireside chat will cover company updates and clinical-stage program progress, per the event format and company participation. According to the company, management participation aims to inform investors about recent developments and strategy.

Where is the TD Cowen 46th Annual Health Care Conference presentation by Enliven Therapeutics (ELVN) hosted?

The presentation is part of the TD Cowen conference and will be available via Enliven's investor relations webcast. According to the company, the live stream link will be posted on the investor relations section of its website.

Is there a cost or registration required to view Enliven Therapeutics (ELVN) webcast at TD Cowen?

The company indicates the webcast can be accessed through its investor relations website without mention of a paywall. According to the company, viewers should visit the investor relations page to access the live stream information.